Posters Overview
With the rapid expansion of peptide and peptidomimetic therapeutics, evaluating their Drug-Drug Interaction (DDI) potential has become an essential part of drug development. Cytochrome P450 3A4 (CYP3A4) inhibition is a primary driver of clinical DDIs. While traditional linear peptides are generally metabolized by proteases and pose low CYP-mediated DDI risks, modified and cyclic peptides may interactwith CYP enzymes. This study aims to evaluate the CYP3A4 (using Midazolam as a specific substrate) direct and time-dependent inhibition (TDI) potential of a diverse panel of peptide therapeutics.

Complete the form to view and download this poster.
Stay Connected
Keep up with the latest news and insights.